Table of Contents Author Guidelines Submit a Manuscript

Liver Fibrosis/Cirrhosis: Pathogenesis, Histopathology, and Therapeutic Approach

Call for Papers

Liver fibrosis/cirrhosis is the common pathological outcome of various chronic liver diseases, such as viral hepatitis, alcoholic steatohepatitis, nonalcoholic steatohepatitis, autoimmune hepatitis, drug-induced liver injury, primary biliary cirrhosis, primary sclerosing cholangitis, and schistosomal cirrhosis. The hepatic parenchymal and mesenchymal cells (i.e., hepatocytes, hepatic stellate cells, biliary cells, Kupffer cells, oval cells, and endothelial cell) undergo phenotypical and functional abnormalities and contribute to the development of liver fibrosis/cirrhosis. Multiple signaling pathways (i.e., TGFβ/Smad, Wnt, MAPK/ERK, P38, and JAK/STAT) and their crosstalk are involved in these processes involving epigenetic dysregulation of DNA/histone methylation, microRNAs, long noncoding RNAs, and circular RNAs. Despite the public health burden, effective preventative and treatment options are lacking due to incomplete understanding of liver fibrosis/cirrhosis pathogenesis.

Here we invite the contribution of original research articles, review articles, and clinical studies on the diagnosis, clinical and pathological features, genetic background, pathophysiological mechanisms, and therapeutic interventions of liver fibrosis/cirrhosis. We solicit contributions to this issue from experts in the fields of hepatology, epidemiology, genetics, biochemistry, molecular biology, and pathology.

Potential topics include but are not limited to the following:

  • Epidemiological survey for chronic liver diseases and related fibrosis/cirrhosis
  • Etiology, pathogenesis, and prevention of hepatic fibrogenesis
  • Noninvasive diagnosis and assessment of liver fibrosis/cirrhosis
  • Pathological analysis for the natural history of liver fibrosis/cirrhosis
  • Genetic, epigenetic, and molecular mechanisms associated with fibrosis progression and resolution
  • Medication intervention and efficacy evaluation
  • Operative therapy for complications of cirrhosis

Authors can submit their manuscripts through the Manuscript Tracking System at

Submission DeadlineFriday, 23 March 2018
Publication DateAugust 2018

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

  • Qin Pan, Shanghai Jiaotong University, Shanghai, China

Guest Editors